Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer Medical Education on ReachMD

Name: Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
Uploaded: 2024-05-06T04:00:00+00:00
Duration: 1 min 46 s
Description: SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette-Guérin in patients with Bacillus Calmette-Guérin-naive high-risk non–mu

Home
Clinical Practice
Oncology and Hematology

CME Learning Centers

CME/CE Topic Areas

Spotlight On:

Lifestyle

Trending Topics

Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer

Program Chapters

Segment Chapters

Playlist:

Recommended

Transcript

Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer

Title

Program Chapters

Segment Chapters

Playlist:

Recommended

Get a Dose of ReachMD in Your Inbox and Practice Smarter Medicine